Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity.

Schaffer, Thomas; Schoepfer, Alain M; Seibold, Frank Werner; Juillerat, Pascal; Swiss Inflammatory Bowel Diseases Cohort Study Group, The (2014). Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn's disease activity. Journal of Crohn's & Colitis, 8(9), pp. 1125-1132. Oxford University Press 10.1016/j.crohns.2014.02.014

Full text not available from this repository. (Request a copy)

BACKGROUND AND AIMS Ficolin-2 is an acute phase reactant produced by the liver and targeted to recognize N-acetyl-glucosamine which is present in bacterial and fungal cell walls. We recently showed that ficolin-2 serum levels were significantly higher in CD patients compared to healthy controls. We aimed to evaluate serum ficolin-2 concentrations in CD patients regarding their correlation with endoscopic severity and to compare them with clinical activity, fecal calprotectin, and CRP. METHODS Patients provided fecal and blood samples before undergoing ileo-colonoscopy. Disease activity was scored clinically according to the Harvey-Bradshaw Index (HBI) and endoscopically according to the simplified endoscopic score for CD (SES-CD). Ficolin-2 serum levels and fecal calprotectin levels were measured by ELISA. RESULTS A total of 136 CD patients were prospectively included (mean age at inclusion 41.5±15.4 years, 37.5% females). Median HBI was 3 [2-6] points, median SES-CD was 5 [2-8], median fecal calprotectin was 301 [120-703] μg/g, and median serum ficolin-2 was 2.69 [2.02-3.83] μg/mL. SES-CD correlated significantly with calprotectin (R=0.676, P<0.001), CRP (R=0.458, P<0.001), HBI (R=0.385, P<0.001), and serum ficolin-2 levels (R=0.171, P=0.047). Ficolin-2 levels were higher in CD patients with mild endoscopic disease compared to patients in endoscopic remission (P=0.015) but no difference was found between patients with mild, moderate, and severe endoscopic disease. CONCLUSIONS Ficolin-2 serum levels correlate worse with endoscopic CD activity when compared to fecal calprotectin or CRP.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Gastroenterologie / Mukosale Immunologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Gastroenterologie / Mukosale Immunologie

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR)

UniBE Contributor:

Schaffer, Thomas; Seibold, Frank Werner and Juillerat, Pascal

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1873-9946

Publisher:

Oxford University Press

Language:

English

Submitter:

Doris Haefelin

Date Deposited:

23 Feb 2015 10:33

Last Modified:

05 Apr 2016 10:17

Publisher DOI:

10.1016/j.crohns.2014.02.014

PubMed ID:

24636141

Uncontrolled Keywords:

CRP, Crohn's disease, Disease activity, Fecal calprotectin, Ficolin-2

URI:

https://boris.unibe.ch/id/eprint/63581

Actions (login required)

Edit item Edit item
Provide Feedback